Analyst Price Targets — TWST
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 16, 2026 10:13 am | Puneet Souda | Leerink Partners | $110.00 | $92.61 | TheFly | Twist Bioscience price target raised to $110 from $80 at Leerink |
| July 14, 2026 10:54 am | Kyle Mikson | Canaccord Genuity | $120.00 | $90.35 | TheFly | Twist Bioscience price target raised to $120 from $90 at Canaccord |
| July 6, 2026 12:01 pm | — | Evercore ISI | $102.00 | $97.95 | TheFly | Twist Bioscience downgraded to In Line from Outperform at Evercore ISI |
| June 29, 2026 11:01 am | — | Guggenheim | $107.00 | $99.84 | TheFly | Twist Bioscience price target raised to $107 from $60 at Guggenheim |
| June 24, 2026 8:51 am | Luke Sergott | Barclays | $95.00 | $85.00 | TheFly | Twist Bioscience price target raised to $95 from $65 at Barclays |
| June 15, 2026 11:44 am | — | Cowen & Co. | $89.00 | $76.17 | TheFly | Twist Bioscience price target raised to $89 from $68 at TD Cowen |
| June 15, 2026 9:43 am | — | Canaccord Genuity | $90.00 | $76.17 | TheFly | Twist Bioscience initiated with a Buy at Canaccord |
| June 15, 2026 9:32 am | — | UBS | $89.00 | $76.17 | StreetInsider | Twist Bioscience (TWST) PT Raised to $89 at TD Cowen |
| June 11, 2026 9:52 am | David Westenberg | Piper Sandler | $85.00 | $67.77 | TheFly | Twist Bioscience initiated with an Overweight at Piper Sandler |
| May 22, 2026 10:29 am | Puneet Souda | Leerink Partners | $80.00 | $58.84 | StreetInsider | Twist Bioscience (TWST) PT Raised to $80 at Leerink |
Latest News for TWST
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 third quarter ended June 30, 2026, before the opening of the market on August 3, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time…
The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health, said it is important to continue studying the impact of GLP-1 medications on users' behavior and public safety as the medications become more…
12,000 shares were exercised from options and sold for a total of ~$673,000 on May 12, 2026. All shares were transacted directly via option exercise and immediate sale; no indirect entities or gifts were involved.
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TWST.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.